DE2127159C2 - IgG-Immunglobulinfraktion und ihre Herstellung - Google Patents
IgG-Immunglobulinfraktion und ihre HerstellungInfo
- Publication number
- DE2127159C2 DE2127159C2 DE19712127159 DE2127159A DE2127159C2 DE 2127159 C2 DE2127159 C2 DE 2127159C2 DE 19712127159 DE19712127159 DE 19712127159 DE 2127159 A DE2127159 A DE 2127159A DE 2127159 C2 DE2127159 C2 DE 2127159C2
- Authority
- DE
- Germany
- Prior art keywords
- solution
- igg
- blood
- plasma
- polyethylene glycol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 108060003951 Immunoglobulin Proteins 0.000 title claims description 17
- 102000018358 immunoglobulin Human genes 0.000 title claims description 17
- 238000004519 manufacturing process Methods 0.000 title description 4
- 210000002381 plasma Anatomy 0.000 claims description 18
- 102000006395 Globulins Human genes 0.000 claims description 17
- 108010044091 Globulins Proteins 0.000 claims description 17
- 239000002202 Polyethylene glycol Substances 0.000 claims description 17
- 229920001223 polyethylene glycol Polymers 0.000 claims description 17
- 238000001556 precipitation Methods 0.000 claims description 17
- 238000005119 centrifugation Methods 0.000 claims description 11
- 210000000601 blood cell Anatomy 0.000 claims description 7
- 238000000926 separation method Methods 0.000 claims description 6
- 210000004027 cell Anatomy 0.000 claims description 3
- 239000012634 fragment Substances 0.000 claims description 3
- 239000000243 solution Substances 0.000 description 47
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 32
- 238000000034 method Methods 0.000 description 26
- 102000004169 proteins and genes Human genes 0.000 description 22
- 108090000623 proteins and genes Proteins 0.000 description 22
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- 230000008569 process Effects 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 238000005194 fractionation Methods 0.000 description 10
- 239000002244 precipitate Substances 0.000 description 10
- 150000002500 ions Chemical class 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 102000004506 Blood Proteins Human genes 0.000 description 7
- 108010017384 Blood Proteins Proteins 0.000 description 7
- 239000004471 Glycine Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 102000009027 Albumins Human genes 0.000 description 6
- 108010088751 Albumins Proteins 0.000 description 6
- 150000001768 cations Chemical class 0.000 description 6
- 239000008363 phosphate buffer Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 102000008946 Fibrinogen Human genes 0.000 description 5
- 108010049003 Fibrinogen Proteins 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 229940012952 fibrinogen Drugs 0.000 description 5
- 239000007974 sodium acetate buffer Substances 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000012064 sodium phosphate buffer Substances 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 229920005654 Sephadex Polymers 0.000 description 4
- 239000012507 Sephadex™ Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Substances OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 230000001376 precipitating effect Effects 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 150000001450 anions Chemical class 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000005342 ion exchange Methods 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000012460 protein solution Substances 0.000 description 3
- BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical compound [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 229920002491 Diethylaminoethyl-dextran Polymers 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 102000013566 Plasminogen Human genes 0.000 description 2
- 108010051456 Plasminogen Proteins 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 238000005349 anion exchange Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000011146 sterile filtration Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 208000034657 Convalescence Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000037319 Hepatitis infectious Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000001166 ammonium sulphate Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000010425 asbestos Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000001226 reprecipitation Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229910052895 riebeckite Inorganic materials 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 229940043517 specific immunoglobulins Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002277 temperature effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/30—Extraction; Separation; Purification by precipitation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE763270A SE348942B (enrdf_load_stackoverflow) | 1970-06-02 | 1970-06-02 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE2127159A1 DE2127159A1 (de) | 1971-12-09 |
| DE2127159C2 true DE2127159C2 (de) | 1981-12-24 |
Family
ID=20271889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19712127159 Expired DE2127159C2 (de) | 1970-06-02 | 1971-06-01 | IgG-Immunglobulinfraktion und ihre Herstellung |
Country Status (8)
| Country | Link |
|---|---|
| AT (1) | AT309678B (enrdf_load_stackoverflow) |
| CA (1) | CA960964A (enrdf_load_stackoverflow) |
| CH (1) | CH572745A5 (enrdf_load_stackoverflow) |
| DE (1) | DE2127159C2 (enrdf_load_stackoverflow) |
| FR (1) | FR2100716B1 (enrdf_load_stackoverflow) |
| GB (1) | GB1344340A (enrdf_load_stackoverflow) |
| NL (1) | NL177599C (enrdf_load_stackoverflow) |
| SE (1) | SE348942B (enrdf_load_stackoverflow) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2751717A1 (de) * | 1976-12-03 | 1978-07-13 | Myer Louis Dr Coval | Neue verbesserte gammaglobuline fuer intravenoese injektion und verfahren zu ihrer herstellung |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE389596B (sv) * | 1974-06-14 | 1976-11-15 | P G S Lindroos | Saett att ur en vaetska innehallande blodsubstanser separera jaernfoereningar fran globin |
| DE2500076C3 (de) * | 1975-01-02 | 1982-11-18 | SCHURA Blutderivate GmbH & Co KG, 4150 Krefeld | Verfahren zur Gewinnung von intravenös-verträglichen Gammaglobulinen |
| AT359641B (de) * | 1978-09-19 | 1980-11-25 | Immuno Ag | Verfahren zur herstellung eines intravenoes ver- abreichbaren antikoerperhaeltigen immunglobulin- praeparates |
| US4315851A (en) * | 1978-12-29 | 1982-02-16 | Kureha Kagaku Kogyo Kabushiki Kaisha | Pharmaceutical composition having antitumor activity |
| AU2010205007A1 (en) * | 2009-01-13 | 2011-07-07 | Ge Healthcare Bio-Sciences Ab | Precipitation of biomolecules with negatively charged polymers |
| AU2010253830B2 (en) | 2009-05-27 | 2016-03-03 | Takeda Pharmaceutical Company Limited | A method to produce a highly concentrated immunoglobulin preparation for subcutaneous use |
| IT1397061B1 (it) | 2009-12-28 | 2012-12-28 | Kedrion Spa | Nuovo processo di purificazione su scala industriale di gammaglobuline da plasma umano per uso industriale. |
| US8796430B2 (en) | 2010-05-26 | 2014-08-05 | Baxter International Inc. | Method to produce an immunoglobulin preparation with improved yield |
| WO2011150284A2 (en) | 2010-05-26 | 2011-12-01 | Baxter International Inc. | Removal of serine proteases by treatment with finely divided silicon dioxide |
| AU2010202125B1 (en) | 2010-05-26 | 2010-09-02 | Takeda Pharmaceutical Company Limited | A method to produce an immunoglobulin preparation with improved yield |
| JP6165143B2 (ja) | 2011-08-26 | 2017-07-19 | バクスアルタ ゲーエムベーハー | 血漿由来の免疫グロブリン組成物の血栓塞栓症の可能性を軽減する方法 |
| TWI629283B (zh) | 2012-02-23 | 2018-07-11 | 巴克斯歐塔公司 | 來自血漿中的免疫球蛋白之ｉ-ｉｖ-１部分沉澱 |
| NZ629867A (en) | 2012-02-29 | 2016-09-30 | Baxalta Inc | Igg stimulated remyelination of peripheral nerves |
| HUE046752T2 (hu) | 2013-02-26 | 2020-03-30 | Baxalta GmbH | Központi idegrendszeri betegségek kezelése immunglobulin G intranazális adagolásával |
| PL2994160T3 (pl) | 2013-05-06 | 2019-10-31 | Baxalta Inc | Leczenie subpopulacji osób z chorobą alzheimera z użyciem połączonej immunoglobuliny g |
| EP4490179A1 (en) | 2022-03-07 | 2025-01-15 | Takeda Pharmaceutical Company Limited | Affinity chromatographic production of clinical human igg products |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL286954A (enrdf_load_stackoverflow) * | 1962-01-03 | |||
| BE713764A (enrdf_load_stackoverflow) * | 1967-05-01 | 1968-09-16 | Baxter Travenol Lab | |
| AT275038B (de) * | 1967-11-15 | 1969-10-10 | Immuno Ag | Verfahren zur Gewinnung von reinem Blutalbumin aus Hämopigmente enthaltenden Proteinlösungen |
-
1970
- 1970-06-02 SE SE763270A patent/SE348942B/xx unknown
-
1971
- 1971-05-28 GB GB1784271A patent/GB1344340A/en not_active Expired
- 1971-06-01 DE DE19712127159 patent/DE2127159C2/de not_active Expired
- 1971-06-01 NL NL7107529A patent/NL177599C/xx not_active IP Right Cessation
- 1971-06-01 CH CH793671A patent/CH572745A5/xx not_active IP Right Cessation
- 1971-06-01 AT AT471971A patent/AT309678B/de active
- 1971-06-01 CA CA114,557A patent/CA960964A/en not_active Expired
- 1971-06-02 FR FR7119993A patent/FR2100716B1/fr not_active Expired
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2751717A1 (de) * | 1976-12-03 | 1978-07-13 | Myer Louis Dr Coval | Neue verbesserte gammaglobuline fuer intravenoese injektion und verfahren zu ihrer herstellung |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2100716A1 (enrdf_load_stackoverflow) | 1972-03-24 |
| AT309678B (de) | 1973-08-27 |
| NL177599B (nl) | 1985-05-17 |
| NL177599C (nl) | 1985-10-16 |
| FR2100716B1 (enrdf_load_stackoverflow) | 1975-06-06 |
| CA960964A (en) | 1975-01-14 |
| SE348942B (enrdf_load_stackoverflow) | 1972-09-18 |
| DE2127159A1 (de) | 1971-12-09 |
| CH572745A5 (enrdf_load_stackoverflow) | 1976-02-27 |
| GB1344340A (en) | 1974-01-23 |
| NL7107529A (enrdf_load_stackoverflow) | 1971-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2127159C2 (de) | IgG-Immunglobulinfraktion und ihre Herstellung | |
| DE2645466C2 (de) | Verfahren zum Isolieren von Albumin aus Plasmaprodukten | |
| EP0013901B1 (de) | Verfahren zur Herstellung einer für die intravenöse Applikation geeigneten Immunglobulinlösung, die IgM in ankonzentrierter Form enthält | |
| DE2720704C2 (de) | Neues Glycoprotein, Verfahren zu seiner Herstellung und seine Verwendung | |
| DE60102144T2 (de) | EINE METHODE ZUR HERSTELLUNG VON IgG | |
| DE2801123C2 (de) | Verfahren zur Herstellung eines intravenös applizierbaren Serumeiweiß-Präparates | |
| EP0000134B1 (de) | Glykoprotein, Verfahren zu seiner Herstellung, seine Verwendung zur Gewinnung von Antiserum sowie das Antiserum | |
| DE3218348A1 (de) | Verfahren zur extraktion von proteinen, insbesondere von lactoferrin und immunglobulinen aus milch | |
| DE3927111A1 (de) | Nicht modifizierte intravenoes verabreichbare igm- und/oder iga-haltige immunglobulinpraeparate und verfahren zu ihrer herstellung | |
| EP0060491B1 (de) | Protein (PP16), Verfahren zu seiner Anreicherung und Gewinnung sowie seine Verwendung | |
| EP0033000A1 (de) | Neues Protein PP15, ein Verfahren zu seiner Herstellung sowie seine Verwendung | |
| DE68911693T2 (de) | Pharmazeutisches mittel für behandlung von menschlichem krebs und verfahren zu seiner herstellung. | |
| DE2403994A1 (de) | Herstellung von antisera | |
| DE2742150C2 (enrdf_load_stackoverflow) | ||
| DE10029705A1 (de) | Herstellung von IgY(AFc)-Antikörpern und deren Verwendung | |
| DE2732998A1 (de) | Verfahren zur herstellung von serumalbumin | |
| DE69030414T2 (de) | Reinigung von Albumin | |
| CH632091A5 (en) | Process for the preparation of an antiserum directed against placenta-specific glycoprotein | |
| EP0035726B1 (de) | Verfahren und diagnostisches Mittel zur direkten Bestimmung des Lipidgehaltes der beta-Lipoproteine des Blutes | |
| DE1617332C3 (de) | Verfahren zum Isolieren eines wasserlöslichen Protein-Metall-Chelats mit antiphlogistischer Wirkung | |
| DE3410694C2 (enrdf_load_stackoverflow) | ||
| EP0029191A1 (de) | Neues Protein PP11, ein Verfahren zu seiner Gewinnung und seine Verwendung | |
| DE10065227A1 (de) | Verfahren zur Isolierung und Reinigung von Eigelb-Antikörpern aus Vogeleiweiß und Verwendung von dadurch erhaltenen Eigelb-Antikörpern | |
| DE3034529C2 (de) | Leukorekrutin: Ein Entzündungsmediatorprotein aus Säugerserum zur Induzierung einer Leukozytosereaktion, Herstellungsverfahren, Gewinnung in molekular einheitlicher, kristallisierbarer und biologisch spezifisch wirkender Form und Leukorekrutin enthaltendes Arzneimittel | |
| DE69711609T2 (de) | Verfahren zum entfernen von unkonventionellen krankheitserregern aus proteinlösungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OD | Request for examination | ||
| D2 | Grant after examination |